Coronavirus Live Count Map India
remove_red_eye 638 Views
COVID-19 Vaccine Updates
#Business And Medicine #Emergency Medicine #Infectious Diseases #Pathology and Lab Medicine #Pharmacist #Public Health #Pulmonary Medicine
An early safety study of Moderna Inc’s COVID-19 vaccine candidate among older adults revealed that virus-neutralizing antibodies were produced at levels similar to those seen in younger adults. The side effects were roughly comparable to high-dose flu shots, stated researchers.
The study, published in the New England Journal of Medicine, was an extension of the Phase I safety trial, first conducted in 18-55 year-olds. Two doses of Moderna’s vaccine - 25 micrograms and 100 micrograms –were tested in 40 adults aged 56 to 70 and 71 and older.
Among older adults given two injections of the 100 microgram dose 28 days apart, the vaccine evoked immune responses that more or less conform to those seen in younger adults… (Reuters, September 30, 2020)
To comment on this article,
create a free account.
Already registered?
.jpg)
• Sir ; Very timely message on this “International Day of Older Persons” that appeared in the NEJM* : a- 2 doses mRNA (Moderna , USA ) vaccine evoked excellent immune responses as seen in younger adults !!!This is excellent news . (First of an immunogenic data for the elderlies) • *Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults , E.J. Anderson and Others DOI: 10.1056/NEJMoa2028436 | September 29, 2020